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Objectives
To develop a focused panel of somatic mutations (SMs)
present in the majority of urothelial bladder cancers (UBCs),
to investigate the diagnostic and prognostic utility of this
panel, and to compare the identification of SMs in urinary
cell-pellet (cp)DNA and cell-free (cf)DNA as part of the
development of a non-invasive clinical assay.
Patients and Methods
A panel of SMs was validated by targeted deep-sequencing of
tumour DNA from 956 patients with UBC. In addition,
amplicon and capture-based targeted sequencing measured
mutant allele frequencies (MAFs) of SMs in 314 urine
cpDNAs and 153 urine cfDNAs. The association of SMs with
grade, stage, and clinical outcomes was investigated by
univariate and multivariate Cox models. Concordance
between SMs detected in tumour tissue and cpDNA and
cfDNA was assessed.
Results
The panel comprised SMs in 23 genes: TERT (promoter),
FGFR3, PIK3CA, TP53, ERCC2, RHOB, ERBB2, HRAS,
RXRA, ELF3, CDKN1A, KRAS, KDM6A, AKT1, FBXW7,
ERBB3, SF3B1, CTNNB1, BRAF, C3orf70, CREBBP,
CDKN2A, and NRAS; 93.5–98.3% of UBCs of all grades
and stages harboured ≥1 SM (mean: 2.5 SMs/tumour). RAS
mutations were associated with better overall survival
(P = 0.04). Mutations in RXRA, RHOB and TERT
(promoter) were associated with shorter time to recurrence
(P < 0.05). MAFs in urinary cfDNA and cpDNA
were highly correlated; using a capture-based approach,
>94% of tumour SMs were detected in both cpDNA and
cfDNA.
Conclusions
SMs are reliably detected in urinary cpDNA and cfDNA. The
technical capability to identify very low MAFs is essential to
reliably detect UBC, regardless of the use of cpDNA or
cfDNA. This 23-gene panel shows promise for the non-
invasive diagnosis and risk stratification of UBC.
Keywords
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Introduction
Despite intensive research into biomarkers for the non-
invasive diagnosis of urothelial bladder cancer (UBC), the
mainstay of detection remains flexible cystoscopy.
Commercial urine tests exist; however, none have been widely
accepted into routine clinical practice due to poor
performance and/or poor evidence [1–3]. Many tests are
based on levels of proteins or RNA and, as these are not
unique to UBC or causally linked to the disease, they tend to
lack specificity and are often not detectably elevated in small
or low-grade tumours [4]. The ideal non-invasive test should
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detect all UBCs whilst not generating false-positive results
from non-malignant urological conditions.
DNA-based biomarkers (methylation, single nucleotide
variants, and copy number variants) can be detected in
urinary DNA and could be used for the non-invasive
detection and characterisation of UBC [5]. Deep sequencing
has enabled both the large-scale identification of somatic
mutations (SMs) in UBC [6] and the sensitive detection of
SMs in urinary DNA [7–11]. However, whole genome
sequencing at sufficient depth to detect SMs at low mutant
allele frequencies (MAFs) remains expensive; thus, to make a
test affordable and interpretable, targeted sequencing of the
minimum number of SMs that provide sufficient information
is desirable. With optimisation of biomarkers and sample
processing, highly sensitive and specific tests could be
developed. Notwithstanding, most urine DNA-based studies
have utilised DNA extracted from the cell pellets of
centrifuged urine (cpDNA) [7,12,13]; however, several studies
have reported that cell-free DNA (cfDNA) from supernatants
of centrifuged urine better represents the genomic changes in
UBC [14–16].
The primary objective of the present study was to develop a
focused panel of SMs present in the majority of UBCs. Our
secondary objectives were to investigate the prognostic utility
of this panel and to compare the identification of these SMs
in urinary cpDNA and cfDNA as a stepping-stone to the
development of a non-invasive diagnostic and prognostic
clinical assay. We used a combination of publicly available
data and in-house exome sequencing to select candidate SMs
for inclusion; many of the SMs are directly involved in UBC
pathogenesis [6]. This panel of SMs in 23 genes was validated
by amplicon deep-sequencing of primary UBCs from 956
patients. We subsequently used deep-sequencing to identify
the tumour tissue SMs in matched urine samples comprising
314 urine cpDNAs and 153 urine cfDNAs. Amplicon
sequencing and a capture-based approach were compared for
SM detection in urinary DNAs.
Patients and methods
SM Panel Development
Using a combination of publicly available data and in-house
exome sequencing, we designed a panel to contain the most
frequent SMs using the minimum amount of sequencing.
Some regions/hotspots were challenging to sequence, or did
not detect mutations, and were excluded. A final panel
covering promoter or exonic regions in 23 genes with 61
amplicons was defined (Table S1); these genes are: telomerase
reverse transcriptase (TERT) (promoter), fibroblast growth
factor receptor 3 (FGFR3), phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit a (PIK3CA), tumour
protein P53 (TP53), ERCC excision repair 2, TFIIH core
complex helicase subunit (ERCC2), Ras homolog family
member B (RHOB), Erb-B2 receptor tyrosine kinase 2
(ERBB2), HRas proto-oncogene, GTPase (HRAS), retinoid X
receptor a (RXRA), E74 like ETS transcription factor 3
(ELF3), cyclin-dependent kinase inhibitor 1A (CDKN1A),
KRAS proto-oncogene, GTPase (KRAS), lysine demethylase
6A (KDM6A), AKT serine/threonine kinase 1 (AKT1), F-box
and WD repeat domain containing 7 (FBXW7), ERBB3,
splicing factor 3b subunit 1 (SF3B1), catenin b1 (CTNNB1),
B-Raf proto-oncogene, serine/threonine kinase (BRAF),
chromosome 3 open reading frame 70 (C3orf70), CREB
binding protein (CREBBP), CDKN2A, and NRAS proto-
oncogene, GTPase (NRAS).
Patients and Samples
Biospecimens were collected as part of the Bladder Cancer
Prognosis Programme (BCPP, ethics approval 06/MRE04/65).
Patients were recruited consecutively from 2005 to 2011 from
10 hospitals in the West Midlands (UK) and gave informed
consent for enrolment based upon initial cystoscopic findings
suggestive of primary UBC. All patients were newly
diagnosed and treatment-na€ıve at biospecimen collection, and
were subsequently treated and monitored according to
contemporary European Association of Urology (EAU)
guidelines (including re-resection where indicated) and EAU
risk groups (for non-muscle-invasive bladder cancer
[NMIBC]). Inclusion and exclusion criteria are detailed
elsewhere [17]. Where necessary, tumour grade and stage
records were amended according to results of early re-
resection or cystectomy. We used the 1973 grade
classification as it was in universal use in the UK at the time
of patient recruitment, is the basis for the European
Organisation for the Research and Treatment of Cancer
(EORTC) and EAU NMIBC risk tables [18], and has
comparable utility to the 2004/2016 classification [19]. For
quality assurance, 10% of diagnostic formalin-fixed paraffin-
embedded tumour samples were retrieved from local
histopathology departments and underwent expert
pathological review. All included tumours were purely or
predominantly TCCs.
Urine (30–50 mL) was placed on ice, centrifuged within 8 h
(600 x g for 10 min), and supernatant and pellet stored at
80 °C. Tissues were collected at transurethral resection of
bladder tumour (TURBT), snap-frozen, and stored at
80 °C. DNA was extracted from tissues (25 mg) and blood
(100 lL) using DNeasy Blood and Tissue kits (Qiagen,
Hilden, Germany). DNA was extracted from urine pellets and
supernatants (10 mL) using Quick-DNA Urine kits (Zymo
Research, Irvine, CA, USA). DNA concentrations were
determined fluorimetrically (Qubit; Thermo Fisher Scientific
Inc., Waltham, MA, USA). We analysed: tumour DNA from
956 patients (along with 402 matched blood samples to
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discriminate between mutations and polymorphisms), urine
cpDNA from 314 of these 956 patients, and paired urine
cfDNA from 261 of these 314 patients where >10 mL urine
supernatant was available; Fig. 1.
Library Preparation and Sequencing
Amplicon libraries were prepared by multiplex-PCR:
primers were divided between two 30-cycle target-specific
PCRs using 5 ng DNA for each and KAPA robust
polymerase. The PCR products were combined and
barcoded in a 15-cycle PCR using Phusion high-fidelity
polymerase [8]. Up to 384 barcoded libraries were
sequenced (2 9 150 bp) on a NextSeq mid-output flow-cell
to a mean read depth of 50009.
Capture-based libraries incorporating unique molecular
identifiers (UMIs) were prepared according to the
manufacturer’s protocol using 20 ng DNA (Cell3TM Target;
Nonacus Ltd, Birmingham, UK) and sequenced as above to a
mean consensus read depth of 22009. Briefly, DNA was
enzymatically fragmented, end-repaired and A-tailed, followed
by ligation of adapters containing UMIs and incorporation of
sample barcodes by PCR. Libraries were pooled and
DNA sequenced from 956 fresh-
frozen bladder tumours to
define SM panel
DNA sequenced from 402 paired
germline (blood) samples to
discriminate between SNPs and
SMs
Urine cpDNA available (and
sequenced) for 314 patients
with SMs
cfDNA extracted from urine of
261 of these patients with 10 mL
urine supernatant available
193 cfDNAs yielding ≥10 ng DNA
40 out of 193 cfDNAs already
used in other experiments*
Tissue + cpDNA + cfDNA trios
n = 153
Fig. 1 Summary of the biospecimens analysed by amplicon sequencing. SNPs, single nucleotide polymorphisms. *Used in the experiments reported by
Russo et al. Bladder Cancer 2018; 4: 41–48.
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hybridised to biotinylated probes overnight, followed by bead
capture, amplification, and sequencing. A detailed workflow is
available at nonacus.com.
Bioinformatics and Data Analysis
Amplicon sequencing reads were aligned to the human
genome (Hg19) using bowtie, and reference and non-
reference read depths extracted using bamreadcount. Only Q
>30 base-calls were considered, and variant detection was
based on the non-reference reads >2.5% of the total read
depth and a minimum of 10 non-reference reads, as
described previously [8]. All mutations included in the 23-
gene panel had to meet the criteria of ≥10% MAF in ≥1
tumour and <2.5% in germline DNA. We used Sanger
sequencing to confirm 50 such mutation calls, with 100%
accuracy. With the exception of the well-known TERT
promotor mutations, only mutations classified as moderate or
high impact by variant effect predictor [20] were considered.
Reads from the capture-based libraries were aligned using
Burrows-Wheeler Alignment tool (BWA), and UMI sequences
were extracted as part of the i7 index read and used to
annotate the aligned reads on a per original molecule basis.
Using a proprietary bioinformatic pipeline, consensus reads
were built where at least two reads contained the same UMI
sequence and had identical genomic start and stop
coordinates. Variant calls required a minimum of four
supporting consensus reads.
Prognostic Utility of Frequently Mutated Genes
Kaplan–Meier curves were constructed to investigate the
effect of mutated genes on outcomes (disease-specific survival,
overall survival, and, where appropriate, progression-free and
recurrence-free intervals). Hazard ratios (HRs) and P values
presented with Kaplan–Meier curves were obtained by fitting
univariate Cox models to the respective datasets. To account
for confounding, base models including key influential factors
were developed for each population and the relevant genes,
then individually included in this model. If ≥2 genes were
found to be significant (P < 0.1) in a population for a
specific outcome when included with the base model, further
Cox models were constructed. These included every
appropriate pair of genes in addition to the base model.
Conditions were applied to the genes that were evaluable and
to the outcomes suitable for modelling. More details are given
in Appendix S1 (Supplementary data).
Results
Frequency of Mutations Across Stages and Grade
of Disease
Patient characteristics are shown in Table 1. The amplicon
sequencing of hotspots/regions of 23 UBC-associated genes in
tumours from 956 patients with UBC are summarised in
Table 2. A total of 916 tumours had ≥1 SM (average of 2.5
SMs/tumour), and ≥1 SM was identified in >93% of tumours
of any grade or stage. We identified 451 unique SMs
comprising: 384 ‘moderate impact’ variants (missense
substitutions), 62 ‘high impact’ variants (likely to result in
loss of functional protein), and five ‘modifier’ variants in the
TERT promotor (Table S2). At presentation, tumours with a
mutation in FGFR3 or AKT1 were five-times less likely to be
muscle-invasive bladder cancer (MIBC) than tumours wild
type for both genes (7% vs 38%); TP53-mutated tumours
were three-times more likely to be MIBC than wild type TP53
tumours (46% vs 15%). Mutations in 11 of the 23 genes
demonstrated statistically significant differences between
NMIBC risk groups and/or MIBC; these genes were AKT1,
CDKN1A, ELF3, ERBB2, ERCC2, FGFR3, KRAS, PIK3CA,
TERT, TP53, and RAS (HRAS, KRAS, and NRAS combined;
Fig. 2).
Table 1 Patient and tumour characteristics.
Variable Tumours (n = 956) Urine cpDNA (n= 314) Urine cfDNA (n = 153) Capture-based analyses
of cpDNA and cfDNA (n = 45)
Age, years, median (range) 71 (26–95) 72 (26–91) 73 (26–88) 74 (44–89)
N (%)
Male 748 (78.2) 247 (78.7) 126 (82.4) 32 (71.1)
Female 208 (21.8) 67 (21.3) 27 (17.6) 13 (28.9)
Grade 1 (G1) 174 (18.2) 53 (16.9) 26 (16.9) 12 (26.7)
Grade 2 (G2) 290 (30.3) 100 (31.8) 42 (27.5) 14 (31.1)
Grade 3 (G3) 478 (50.0) 153 (48.7) 80 (52.3) 19 (42.2)
Unknown (U) 14 (1.5) 8 (2.5) 5 (3.3) 0
CIS [G1/G2/G3/U] 3 [0/0/3/0] (0.3) 3 [0/0/3/0] (1.0) 3 [0/0/3/0] (2.0) 0
pTa [G1/G2/G3/U] 466 [169/224/71/2] (48.7) 143 [52/73/17/1] (45.5) 64 [25/30/9/0] (41.8) 26 [12/11/3/0] (57.8)
pT1 [G1/G2/G3/U] 263 [5/58/194/6] (27.5) 89 [1/24/60/4] (28.3) 42 [1/11/28/2] (27.5) 9 [0/2/7/0] (20.0)
pT2 [G1/G2/G3/U] 224 [0/9/209/6] (23.4) 79 [0/3/73/3] (25.2) 44 [0/1/40/3] (28.7) 10 [0/1/9/0] (22.2)
CIS, carcinoma in situ; pT, pathological T stage.
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Prognostic Utility of Frequently Mutated Genes
Across the entire cohort, TERT, FGFR3, TP53 and RAS were
significantly associated with overall and disease-specific
survival (Fig. 3). RAS mutations remained significantly
associated with better overall survival when adjusting for
EAU risk factors (HR 0.60, 95% CI 0.37–0.97; P = 0.04).
There were insufficient events to adjust by EAU risk factors
for disease-specific survival.
The influence of mutated genes on time to recurrence and
overall survival was investigated in patients with NMIBC
(there were too few events to consider progression and
disease-specific survival). Mutations in RXRA, RHOB and the
TERT promoter were associated with shorter time to
recurrence (P < 0.05; Fig. 4), and remained significant after
adjusting for gender and EAU risk group. RAS mutations
were significantly associated with better overall survival after
adjusting for gender and EAU risk group (P < 0.01).
We also analysed the influence of SMs on time to progression
and disease-specific survival in patients with high-risk
NMIBC; the association between FGFR3 mutations and
longer time to progression approached significance (HR 0.35,
95% CI 0.12–1.05; P = 0.06). None of the genes were
significantly associated with disease-specific survival; although
survival curves for RAS mutant and wildtype in high-risk
NMIBC patients diverged, there were too few events to
calculate statistical significance by Cox model (Appendix S1.
Supplementary data).
In patients with MIBC, adjusted Cox models accounting for
gender showed improved disease-specific survival associated
with FGFR3 mutations (HR 1.76, 95% CI 1.05–2.93; P = 0.03)
and worse overall survival associated with TP53 mutations
(HR 0.73, 95% CI 0.53–0.99; P = 0.04).
DNA Yield from Urine Pellets and Urine Supernatants
In 261 paired urinary cfDNAs and cpDNAs, the median
cfDNA yield was 4.5 ng/mL of urine compared with 52 ng/
mL for cpDNA. Using a minimum DNA input of 10 ng for
amplicon sequencing enabled 74% of urine supernatants to be
utilised, compared with >90% of pellets. Across the 261 urine
samples there was no correlation between supernatant and
pellet DNA yields (Fig. 5).
Detection of SMs in Paired Tumour and cpDNA
cpDNA was available from 314 patients with SMs identified
in their tumour DNA. These UBCs had 903 SMs in total with
a mean of 2.9 SMs/tumour. Amplicon sequencing of cpDNAs
identified 645 (71.4%) of the 903 mutations at >2.5% MAF.
In all, ≥1 SM was found in 240 cpDNAs (76.4%). The
median MAF across all cpDNAs was 20.6%; Grade 1, 2 and 3
Table 2 Mutation frequencies across grades and stages of bladder cancer.
Gene G1pTa
(n = 169)
G2pTa
(n = 224)
G3pTa
(n = 71)
G2pT1
(n = 58)
G3pT1
(n = 194)
≥pT2
(n = 224)
Other
(n = 16)
Total
(n= 956)
TERT 63.9 74.6 69.0 81.0 79.9 87.1 75.0 76.7
FGFR3 71.6 72.8 42.3 51.7 27.3 12.9 25.0 45.0
PIK3CA 37.9 38.8 29.6 32.8 21.6 30.4 31.3 32
TP53 4.7 9.4 23.9 15.5 41.8 53.6 37.5 27.4
ERCC2 10.1 12.9 23.9 12.1 21.1 10.3 18.8 14.3
RHOB 9.5 6.3 4.2 10.3 8.2 6.3 12.5 7.4
ERBB2 3.6 4.9 9.9 5.2 12.9 4.9 12.5 6.8
HRAS 7.7 4.9 1.4 3.4 6.2 2.7 0.0 4.7
RXRA 1.8 4.9 5.6 8.6 7.2 3.6 0.0 4.7
ELF3 5.3 0.4 4.2 10.3 6.7 4.5 12.5 4.6
CDKN1A 0.6 3.1 8.5 1.7 7.2 4.5 0.0 4.1
KRAS 5.3 0.9 4.2 10.3 3.6 3.6 12.5 3.9
KDM6A 1.2 4.9 4.2 8.6 2.1 2.2 0.0 3.1
AKT1 8.3 4.0 1.4 0.0 0.5 0.9 0.0 2.8
FBXW7 1.8 1.8 2.8 5.2 3.1 3.1 6.3 2.7
ERBB3 1.8 1.8 4.2 0.0 2.6 3.6 0.0 2.4
SF3B1 0.0 1.3 4.2 3.4 1.5 3.6 6.3 2.1
CTNNB1 0.0 2.7 2.8 1.7 1.0 2.7 6.3 1.9
BRAF 1.2 0.4 4.2 1.7 1.5 0.9 6.3 1.4
C3orf70 0.0 1.3 2.8 0.0 1.0 2.2 6.3 1.4
CREBBP 0.0 1.8 1.4 1.7 1.5 1.8 0.0 1.4
CDKN2A 1.2 0.0 0.0 0.0 1.5 1.8 6.3 1.0
NRAS 1.2 0.9 2.8 1.7 0.5 0.4 0.0 0.9
Any gene 93.5 95.5 94.4 98.3 96.9 97.8 93.8 96.0
Results are presented as the percentage of tumours in each category with a mutation in each (or any) gene. The ‘other’ category includes three cases of solitary Tis, five cases of
G1pT1, and eight NMIBCs where grade was not recorded. G1, Grade 1; G2, Grade 2; G3, Grade 3.
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Fig. 2 Genes in which tumour mutation frequency demonstrated significant differences between NMIBC risk groups and/or MIBC. HRAS, KRAS, NRAS
have been combined as RAS. pink, wild type; magenta, mutated. LR, low-risk NMIBC; IR, intermediate-risk NMIBC; HR, high-risk NMIBC.
© 2019 The Authors
BJU International Published by John Wiley & Sons Ltd on behalf of BJU International 537
23-gene panel for urinary UBC diagnosis
disease had median MAFs of 3.7%, 22.5%, and 25.3%,
respectively.
Detection of SMs in Paired Tumour and Urine cfDNA
Amplicon sequencing was used to analyse cfDNA from 153
patients with tumour SMs, cpDNA data, and >10 ng cfDNA.
Of 437 SMs identified in tumour DNA, 353 were detected in
urinary cfDNA (80.7%), and ≥1 SM was found in 128
cfDNAs (83.8%). This compares favourably with the detection
of 326 SMs in the corresponding cpDNAs (74.6%), and the
detection of ≥1 SM in 118 cpDNAs (77.3%). The allele
frequencies of mutations detected in 153 paired cpDNAs and
cfDNAs were positively correlated (rs = 0.86; Fig. 6), with a
median MAF of 24.5% in cfDNA vs 18.9% in cpDNA
(P < 0.001). The median MAF in Grade 1, 2 and 3 disease
was 2.2%, 26.1% and 36.7% for cfDNA and 3.2%, 20.4% and
29.8% for cpDNA, respectively. The proportions of mutations
identified in individual genes in each type of DNA (tumour
tissue DNA, urinary cpDNA, and urinary cfDNA) are shown
in Fig. 7.
Capture-Based cpDNA and cfDNA Analysis
In paired cpDNAs and cfDNAs from 45 patients, SMs were
detected by a capture-based method (whereby consensus read
building removes PCR and sequencing errors permitting
detection of MAFs >10-fold lower than standard amplicon
sequencing [21]). All 45 pairs of samples were from patients
with SMs identified in tumour tissue; for 30 patients, SMs
were not detected in cpDNA by amplicon sequencing (‘false-
negatives’) and for 15 patients they were (‘true positives’). All
expected tumour SMs were detected in the true positive
cpDNAs and corresponding cfDNAs; MAFs from the
amplicon and capture-based methods were closely aligned
(Fig. 8a) confirming the strong correlation between cpDNA
and cfDNA MAFs (Fig. 8b).
Capture-based analysis of the ‘false negative’ cpDNAs
identified SMs in 26/30 patients (86.7%), and 56/72 of all
tumour SMs (77.8%); analysis of the corresponding cfDNAs
identified SMs in 24/30 patients (80.0%) and 54/72 of all
tumour SMs (75.0%).
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Fig. 3 The effect of the six commonest mutated genes on disease-specific survival across the entire cohort of 956 patients (wild = wild type).
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Discussion
DNA-based urinary biomarkers have emerged as the
frontrunners for the non-invasive detection of UBC. The ideal
DNA-based non-invasive diagnostic test for bladder cancer
would utilise the minimal amount of sequencing to obtain
optimal sensitivity across all grades and stages of disease,
whilst utilising a DNA substrate abundant in the majority of
urine samples. In the present study, we describe such a test,
identifying 451 SMs in 23 genes that, overall, were present in
96% of UBCs. Many commonly mutated large tumour
suppressor genes (e.g. KDM6A, KMT2D) with SMs widely
distributed across the gene were unsuitable for inclusion.
Notwithstanding, this panel demonstrates potential for non-
invasive detection of UBC via urinary DNA.
The distribution of common SMs across stages and grades of
UBC in this cohort is consistent with previous data [22,23].
Also consistent with the literature [24–26], we found that
TP53, FGFR3 and TERT promoter mutations are predictive of
survival in univariate analyses, but are not significant in
multivariate analyses adjusting for accepted risk factors [1].
RAS mutations are associated with improved survival and
remain so after adjusting for EAU risk factors. As RAS
mutations are known activators of a known oncogene, it is
unlikely that they are beneficial per se and more likely that
they co-occur with favourable events or are mutually
exclusive with unfavourable events. We caution that RAS
mutations have not been reported as prognostic in UBC in
other large datasets [6,23]. There have been contradictory
reports as to whether PIK3CA mutations are prognostic
[23,27,28], but we demonstrate no relationship. Additionally,
we find that RXRA, RHOB and TERT mutations are all
associated with decreased recurrence-free interval in NMIBC.
We have shown that 71% of SMs harboured by UBCs can be
detected in corresponding urine cpDNA by amplicon
sequencing (2.5% MAF threshold) resulting in the detection
of 76% of mutation-positive tumours. Capture-based analysis
of cpDNAs confirmed that the SMs detected at >2.5% MAF
by amplicon sequencing were genuine, and that decreasing
the limit of detection to 0.2% MAF increases the number of
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Fig. 4 SMs with a significant influence on time to recurrence in NMIBC (wild = wild type).
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SMs detected. If we had applied the capture-based approach
to all cpDNAs we hypothesise that up to 94% of all SMs
could have been detected, potentially identifying 95% of
mutation-positive tumours.
Using amplicon sequencing, tumour SMs were detected in
78% of cfDNAs, and cfDNA and cpDNA MAFs were
correlated, as previously demonstrated [29]. There was a
small (5%) but significant (P < 0.001) increase in average
MAF in cfDNA relative to cpDNA. We verified these data
using a capture-based approach with improved analytical
sensitivity; this method is less error-prone, extremely sensitive
(due to UMIs and consensus reads), and quantitative
(sequencing reads can be mapped back to individual DNA
molecules). Using this method we found that all tumour SMs
that can be detected at >2.5% MAF in cpDNA were also
detected in cfDNA, and that 80% of the SMs missed in
cpDNA at >2.5% MAF can be detected in cfDNA at >0.2%
MAF. We hypothesise that if the capture-based method had
been applied to all cfDNAs then up to 95% of all SMs could
have been detected, potentially identifying 97% of mutation-
positive tumours.
Our present data also show that sequencing selected regions
of 10s of genes (rather than 100s of genes) could provide the
basis for a non-invasive diagnostic test for UBC, with high
sensitivity for all grades and stages of disease. The majority of
false negative urine samples were due to undetectably low
MAFs in cpDNA and cfDNA, and not due to the absence of
mutations in the tumour. Thus, the technical ability to
identify very low MAFs should be a key component of any
such test.
Other workers have also utilised cpDNA and targeted deep
sequencing for the identification of genomic alterations in
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urine samples from patients with UBC [7,9,30]; however, few
studies have directly compared cpDNA and cfDNA by
targeted deep sequencing in this setting [11,31]. Although
cpDNA is conventionally utilised for urinary biomarker
studies (principally due to higher yields than cfDNA), we
have shown that SM detection in urinary cfDNA works as
well as (or marginally better than) SM detection in cpDNA.
Notwithstanding, >25% of urine supernatants yielded <1 ng/
mL DNA and were unsuitable for analysis; thus, the
abundance of urinary cpDNA likely outweighs the marginal
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advantages of cfDNA. Preparing cpDNA and cfDNA in
parallel, and then either analysing both, or cpDNA whenever
possible and cfDNA in cases where cpDNA extraction fails,
would reduce the number of untestable samples. To improve
cfDNA yields per urine sample in the future, the development
of economical and efficient methods to extract cfDNA from
larger urine volumes (>100 mL) would facilitate the
widespread applicability of urinary cfDNA analysis.
Our primary objective was to develop a focused panel of SMs
present in the majority of UBCs and, secondarily, to
investigate its prognostic utility and detection in cpDNA and
cfDNA as a stepping-stone to the development of a clinical
diagnostic assay. Validation in another cohort of patients
with UBC will be required to translate these findings, as well
as the presentation of sensitivities and specificities from
participants with and without UBC; this work is ongoing.
However, we consider the data presented here to be of
interest to both the UBC and liquid biopsy research
communities, with additional novel findings relating to
prognosis. Furthermore, recent evidence also suggests that
mutations in four of the genes within our panel (ERCC2,
FGFR3, PIK3CA and ERBB2) are associated with response to
cisplatin-based neoadjuvant chemotherapy for MIBC [32,33],
and FGFR inhibitors are in clinical trials for patients with
advanced MIBC [34], thus demonstrating additional potential
utility of our panel. However, with regard to treatment
selection for FGFR inhibition (and of also relevance to
ERBB2), it was noticeable that the identification of actionable
mutations by amplicon sequencing was superior in tumour
tissue DNA than in urinary DNA (Fig. 7); notwithstanding,
the collection, shipping, handling and processing of liquid
biopsies for such assays is generally easier than for
conventional tumour biopsies, with the added benefits of
abundance and the potential for repeat testing.
It should also be noted that patients in the present study all
had primary UBC with urine samples collected pre-TURBT
and tumour samples collected at TURBT; confirmation is
required regarding the sensitivities and specificities of
mutation detection in UBC surveillance urine samples (both
NMIBC surveillance, and MIBC surveillance following
bladder-preservation), and the potential confounding effects
of urothelial field change, radiotherapy, and other urological
conditions. Again, this work is ongoing.
Conclusions
We have described key components of a potential non-
invasive diagnostic test for bladder cancer based upon a 23-
gene panel, and which also demonstrates additional utility for
risk stratification and the possibility of therapeutic response
prediction in specific settings. SMs can be reliably detected in
urinary cpDNA and cfDNA, although the technical capability
to identify very low MAFs is essential to reliably detect UBC
regardless of the use of cpDNA or cfDNA. Given the higher
yields of cpDNA per urine sample, cfDNA could be used to
corroborate cpDNA results or if cpDNA yields are
insufficient.
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